Updates to Prescribing Medicines in Pregnancy database, December 2022


The Prescription Medication Database in Pregnancy has been updated with the following new entries:

  • aciminib hydrochloride – pregnancy category D
  • Aniflorumab – pregnancy category C
  • Bilastine – pregnancy category B3
  • Bimekizumab – pregnancy category C
  • Clobetasol – pregnancy category B3
  • difelikefalin – pregnancy category B1
  • Diloximer Fumarate – Pregnancy Category B3
  • dostarlimab – pregnancy category D
  • Estetrol (as monohydrate) – Pregnancy Category B3
  • Farisimab – pregnancy category D
  • Influenza Vaccine (Seasonal; Recombinant) – Pregnancy Category B1
  • Maribavir – pregnancy category D
  • Mobocertinib succinate – pregnancy category D
  • Osilodrostat – pregnancy category D
  • patisiran – pregnancy category D
  • Pegcetaco Plan – Pregnancy Category B3
  • Pemigatinib – pregnancy category D
  • ponesimod – pregnancy category D
  • Pneumococcal Vaccine, Polysaccharide Conjugate – Pregnancy Category B1
  • Rabies Vaccine (Inactivated) – Pregnancy Category B2
  • Selumetinib – pregnancy category D
  • selinexor – pregnancy category D
  • somapacitan – pregnancy category B1
  • Somatrogon – pregnancy category B1
  • sotorasib – pregnancy category B3
  • Tepotinib – pregnancy category D
  • Tixagevimab; cilgavimab – pregnancy category B2
  • Trastuzumab deruxtecan – pregnancy category D
  • Treosulfan – pregnancy category D
  • Vosolitide – pregnancy category B2

The following entries have been modified.

  • COVID-19 vaccine – ChAdOx1-S – Pregnancy category from B2 to B1
  • COVID-19 Vaccine – Elasomeran – Renamed: COVID-19 Vaccine (mRNA)
  • COVID-19 vaccine – tozinameran – renamed: COVID-19 vaccine (mRNA)
  • Pneumococcal vaccine, 23-valent polysaccharide or 10- or 13-valent conjugate – name change: Pneumococcal vaccine, capsular polysaccharide
  • COVID-19 Vaccine – SARS-CoV-2 rS (NVX-CoV2373) – Renamed: COVID-19 Vaccine (Recombinant Protein)
/Release. This material from the original organization/author may be of a point-in-time nature, edited for clarity, style, and length. Views and opinions expressed are those of the author is. View the full text here.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *